Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Long-Term Investments (2016 - 2023)

BioCorRx (BICX) has disclosed Long-Term Investments for 11 consecutive years, with $44520.0 as the latest value for Q2 2023.

  • Quarterly Long-Term Investments changed 0.0% to $44520.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $44520.0 through Jun 2023, changed 0.0% year-over-year, with the annual reading at $44520.0 for FY2022, 0.0% changed from the prior year.
  • Long-Term Investments hit $44520.0 in Q2 2023 for BioCorRx, roughly flat from $44520.0 in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $53793.0 in Q3 2019 to a low of $13422.0 in Q1 2019.
  • Historically, Long-Term Investments has averaged $41292.7 across 5 years, with a median of $44520.0 in 2020.
  • Biggest five-year swings in Long-Term Investments: soared 300.78% in 2019 and later fell 17.24% in 2020.
  • Year by year, Long-Term Investments stood at $41936.0 in 2019, then rose by 6.16% to $44520.0 in 2020, then changed by 0.0% to $44520.0 in 2021, then changed by 0.0% to $44520.0 in 2022, then changed by 0.0% to $44520.0 in 2023.
  • Business Quant data shows Long-Term Investments for BICX at $44520.0 in Q2 2023, $44520.0 in Q1 2023, and $44520.0 in Q4 2022.